0001410939-23-000080.txt : 20230519 0001410939-23-000080.hdr.sgml : 20230519 20230519174759 ACCESSION NUMBER: 0001410939-23-000080 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230517 FILED AS OF DATE: 20230519 DATE AS OF CHANGE: 20230519 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Blumenkranz Mark S. CENTRAL INDEX KEY: 0001614869 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36080 FILM NUMBER: 23941748 MAIL ADDRESS: STREET 1: C/O 1LIFE HEALTHCARE, INC. STREET 2: ONE EMBARCADERO CENTER, SUITE 1900 CITY: SAN FRANCISCO STATE: CA ZIP: 94111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IVERIC bio, Inc. CENTRAL INDEX KEY: 0001410939 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208185347 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: (609) 474-6755 MAIL ADDRESS: STREET 1: 8 SYLVAN WAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Ophthotech Corp. DATE OF NAME CHANGE: 20070828 4 1 wk-form4_1684532862.xml FORM 4 X0407 4 2023-05-17 0 0001410939 IVERIC bio, Inc. ISEE 0001614869 Blumenkranz Mark S. C/O IVERIC BIO, INC. 8 SYLVAN WAY PARSIPPANY NJ 07054 1 0 0 0 0 Restricted Stock Units 2023-05-17 4 A 0 7500 0 A Common Stock 7500 7500 D Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units. Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc. /s/ Todd D.C. Anderman, as Attorney-in-Fact for Mark S. Blumenkranz 2023-05-19